Clinical trial Recruiting at 2 sites Interventional Ages 18 to 75

Abdominal wall closure after open cancer surgery using a bioabsorbable device

Official title: A Prospective, Multi-Center, Single Arm, Feasibility Study Using REBUILD Bioabsorbable™ for Closure of the Abdominal Wall After Oncologic Laparotomy

Run by AbSolutions Med Inc. · NCT05041530 · Data updated 2026-11-12

This study tests a bioabsorbable device called REBUILD to see if it safely helps close the abdominal wall after open cancer surgery in adults.

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment30 (estimated)
SponsorAbSolutions Med Inc.
Industry-sponsored
Locations2 sites (Medellín, Antioquia and 1 other locations)
StatusRecruiting
StartedJune 17, 2022
Main results expectedMarch 2023
Study endsJune 2023
Registry record updatedDecember 27, 2022
Trial IDNCT05041530 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18-75 undergoing elective open oncologic laparotomy intending to cure the cancer.

Probably not a fit

Patients with prior failed ventral/incisional hernia repair, active infection at the surgical site, planned palliative surgery, pregnancy, or conditions affecting follow-up may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a first-in-human, prospective, non-randomized study involving multiple centers to describe how REBUILD performs when used with standard sutures during open oncologic laparotomies. The primary safety measure is device-related adverse events within the study period, and the primary performance measure is the integrity of the abdominal wall at one year based on physical exams, with CT confirmation if available. The study focuses on descriptive data to characterize safety and how well the device helps maintain closure. Eligible participants are adults 18-75 undergoing planned open oncologic laparotomy and able to consent and comply with follow-up visits.

Why it matters

Potential benefit: If successful, the device could improve the stability of abdominal wall closures after cancer-related open surgeries.

How similar studies have gone: Previous first-in-human approaches have shown that similar closure devices can be safe and feasible, but this exact device is being evaluated for first-in-human use in this surgical context.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patient is 18-75 years of age
2. Patient is scheduled for oncologic, open, elective, intent-to-cure laparotomy
3. Patient is able to provide written informed consent
4. Patient is able and willing to comply with all study requirements

Exclusion Criteria:

1. Patient is scheduled for a palliative procedure
2. Patient has had previous failed surgical repair of a ventral or incisional hernia
3. Patient has a current infection at the intended surgical site
4. Patient is participating in a concurrent investigational medical device study
5. Patient is pregnant or planning on becoming pregnant during the study period
6. Patient has a history of psychological condition, drug or alcohol misuse which may interfere with their ability to be compliant with post-operative visits.

Where it's running

  • Clinica Medellin
    Medellín, Antioquia, Colombia
    Recruiting
  • Clinica Las Americas
    Medellín, Colombia
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.